X
[{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Exalys Therapeutics
Filters
Companies By Therapeutic Area
Details:
The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.
Lead Product(s):
Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Catalys Pacific
Deal Size: $15.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
July 16, 2020